NRXP
NRx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.46
+0.73%Aug 17, 2026, 11:00 UTC
NRx Pharmaceuticals completed the first-cycle FDA review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, and submitted the sole remaining manufacturer's attestation on the vial to the FDA.
Source:Aug 15, 2026, 01:16 UTC
NRx Pharmaceuticals, Inc. reported a Q2 2026 loss of $0.18 per share, missing the Zacks Consensus Estimate of a loss of $0.09, and compared to a loss of $0.98 per share a year ago.
Source:Aug 10, 2026, 14:05 UTC
NRx Pharmaceuticals completed the first-cycle FDA review of its abbreviated new drug application for preservative-free ketamine, with one remaining issue related to the product's vial connector.
Jun 25, 2026, 11:00 UTC
NRx Pharmaceuticals subsidiary HOPE Therapeutics began treating first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, Florida.
Source:Jun 24, 2026, 17:18 UTC
Kadima Neuropsychiatry Institute and Dr. David Feifel filed a lawsuit against NRx Pharmaceuticals, its subsidiary Hope Therapeutics Inc., and HTX Management Company LLC in San Diego County Superior Court, alleging breach of contract and misrepresentation related to an acquisition agreement.
Source:Jun 23, 2026, 15:05 UTC
ZETA SURGICAL and HOPE Therapeutics treated the first patient with the Zeta TMS Navigation System at a HOPE Therapeutics clinic in Sarasota, Florida.
Jun 22, 2026, 11:00 UTC
The FDA granted an expanded access protocol for NRx Pharmaceuticals' NRX-101 to augment transcranial magnetic stimulation in treating depression.
Source:Jun 4, 2026, 21:12 UTC
NRx Pharmaceuticals closed a $22.3 million underwritten public offering of common stock, including the exercise of the underwriters' option.